Related references
Note: Only part of the references are listed.HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
HER2 and response to paclitaxel in node-positive breast cancer
Daniel F. Hayes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Gene copy mapping of the ERBB2/TOP2A region in breast cancer
KK Jacobson et al.
GENES CHROMOSOMES & CANCER (2004)
Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
RE Mueller et al.
GENES CHROMOSOMES & CANCER (2004)
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
ST Brookes et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
A Di Leo et al.
ANNALS OF ONCOLOGY (2001)
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
G Konecny et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
